1/224
Looks like no tags are added yet.
Who established the four-group classification of protein therapeutics, and when?
Leader et al. (2008): proteins classified by enzymatic/regulatory, targeting, vaccine, or diagnostic action.
Which review reported mAbs as 53.5% of 2018–2022 biopharmaceutical approvals?
Walsh & Walsh (2022).
What did Kaplon et al. (2020) report about mAb targets?
Just 10 targets accounted for about 42% of historically approved mAbs.
What was Uhlén et al. (2015) known for in the notes?
Mapping the human tissue proteome: ~3,000 secreted-protein and ~5,500 membrane-protein genes.
What clinical issue did Roda et al. (2016) examine?
Primary non-response and subsequent loss of response during anti-TNF therapy.
What did Vu & Claret (2012) review?
Primary and acquired resistance to HER2-directed trastuzumab; need for predictive biomarkers.
What did O’Connell et al. (2002) compare?
Multivalent versus monovalent phage display using scFvs; selection/expression performance.
What did Gourgari et al. (2017) review?
Engineered insulin analogues classified by altered onset and duration of action.
Who invented hybridoma technology, and in what year?
Köhler and Milstein, 1975; fusion of antigen-specific B cells with immortal myeloma cells.
Who shared the 1984 Nobel Prize for monoclonal-antibody-related work?
Köhler, Milstein and Niels Jerne.
What was the first FDA-approved therapeutic monoclonal antibody and year?
Murine muromonab-CD3 (OKT3), 1986.
Which first recombinant human insulin was approved in 1982?
Humulin: recombinant human insulin.
Which year was trastuzumab approved, according to the lecture?
1998.
Which year was adalimumab approved, according to the lecture?
2002; a fully human anti-TNF mAb.
What did Hudis (2007) describe?
Trastuzumab mechanisms, HER2 signalling and cardiotoxicity.
What was the key message of Carter & Lazar (2018)?
Antibody target difficulty: accessible “low-hanging” targets versus challenging “high-hanging” ones.
What did Chan, Martyn & Carter (2025) review?
50 years of antibody development, newer formats, subcutaneous delivery and AI-assisted design.
Which 2011 paper updated the hallmarks of cancer?
Hanahan & Weinberg (2011): emerging hallmarks plus enabling characteristics.
What did Sharma & Allison (2015) emphasize?
T-cell activation/checkpoint biology and rationale for treating hot versus cold tumours.
What did Ribas & Wolchok (2018) examine?
Checkpoint therapy mechanisms and resistance involving JAK1/2 or β2-microglobulin.
What discovery earned Karikó and Weissman the 2023 Nobel Prize?
Nucleoside-base modifications enabling effective mRNA vaccine development.
Which authors reviewed blinatumomab pharmacology in 2019?
Burt, Warcel and Fielding: half-life, continuous infusion, CRS and neurotoxicity.
What did Kitazawa et al. (2012) demonstrate?
Preclinical bispecific FIXa–FX bridging that mimics FVIIIa cofactor function.
What did Guo et al. (2021) explain?
Amivantamab dual EGFR/MET binding, Fc engineering and activity in TKI-resistant NSCLC.
What did Kalra & Sahay (2020) review?
Oral semaglutide as a GLP-1 receptor agonist for type 2 diabetes.
What did Drucker (2025) review?
GLP-1-based therapies for diabetes, obesity and wider indications.
What did Wilson & Castle (2020) review?
Recent advances in insulin therapy and delivery.
What did Bain & Brazil (2003) describe?
Adalimumab, the fully human anti-TNF therapeutic antibody.
What did Johnson & Jiang (2023) review?
Infection, autoantibodies and the development of autoimmunity.
What did Monteleone et al. (2023) review?
Shared and distinct pathogenic and clinical features of inflammatory diseases.
Which study established a survival benefit from adding trastuzumab to first-line chemotherapy?
Slamon et al.: metastatic HER2-positive breast cancer.
What was time to progression in the pivotal Slamon trastuzumab study?
7.4 months with trastuzumab + chemotherapy versus 4.6 months with chemotherapy alone.
What was overall survival in the pivotal Slamon trastuzumab study?
25.1 months with trastuzumab + chemotherapy versus 20.3 months with chemotherapy alone.
Which three adjuvant trastuzumab trials are cited?
HERA, BCIRG 006 and NCCTG N-9831.
What recurrence-risk reductions are attributed to adjuvant trastuzumab in the notes?
Approximately 36–51%, depending on trial and analysis.
What death-risk reductions are attributed to adjuvant trastuzumab in the notes?
Approximately 34–41%, depending on trial and analysis.
What toxicity strongly limits trastuzumab with anthracyclines?
Cardiac dysfunction/heart failure; HER2 signalling supports cardiomyocyte survival and repair.
What heart-failure incidences with trastuzumab combinations are quoted?
27% with anthracyclines versus 13% with paclitaxel; context-specific historical estimates.
What did Hodi et al. (2010) demonstrate for ipilimumab?
Phase III overall survival benefit in metastatic melanoma, with immune-related toxicities.
What immune checkpoint does ipilimumab block?
CTLA-4; it permits stronger CD28-mediated T-cell priming.
What approximate objective response rate is quoted for ipilimumab monotherapy?
~15% in metastatic melanoma; responses could be durable.
What long-term survival observation is quoted for ipilimumab?
~20% survived more than 4 years in the cited historical context.
What did KEYNOTE-006 compare?
Pembrolizumab versus ipilimumab in advanced melanoma.
What did Robert et al. (2015) report in KEYNOTE-006?
Pembrolizumab improved progression-free and overall survival versus ipilimumab.
What approximate response rate is quoted for nivolumab + ipilimumab in melanoma?
~60%; combination has higher toxicity than single-agent PD-1 blockade.
What 3-year OS figures are quoted for combination versus nivolumab alone?
58% with nivolumab + ipilimumab versus 52% with nivolumab alone.
Why can MSI-high / mismatch-repair-deficient tumours respond to PD-1 blockade?
High mutation/neoantigen burden can increase T-cell recognition.
What is the quoted ORR for checkpoint blockade in Hodgkin lymphoma?
87% in the specific cited context; not a universal rate for all studies.
What is the quoted ORR for checkpoint blockade in desmoplastic melanoma?
70% in the specific cited context.
What is the quoted ORR for checkpoint blockade in MSI-high cancer?
53% in the specific cited context.
What response rate is quoted for PD-L1-negative patients on nivolumab?
17%; illustrates that PD-L1 negativity does not guarantee no response.
What exploratory biomarker increased after presurgical ipilimumab in bladder cancer?
ICOS expression on CD4+ T cells in tumour and blood.
Which chromosomal change contributes to PD-L1 upregulation in classical Hodgkin lymphoma?
Chromosome 9p24.1 amplification affecting PD-L1/PD-L2 and JAK2.
Which approved melanoma combination blocks PD-1 and LAG-3?
Nivolumab + relatlimab (Opdualag).
What did the KATHERINE trial compare?
Adjuvant T-DM1 versus trastuzumab after residual invasive HER2+ breast cancer post-neoadjuvant therapy.
What were the KATHERINE 3-year invasive disease-free survival rates?
88.3% for T-DM1 versus 77.0% for trastuzumab.
What was the KATHERINE invasive recurrence/death hazard ratio?
HR 0.50 (95% CI 0.39–0.64; p < 0.001).
What does HR 0.50 mean in KATHERINE?
Approximately 50% lower hazard of invasive recurrence or death, not 50 percentage points higher iDFS.
What KATHERINE toxicity caused discontinuation in 4.2%?
Thrombocytopenia (decreased platelet count).
What KATHERINE toxicity caused discontinuation in 1.5%?
Peripheral sensory neuropathy.
What did DESTINY-Breast04 compare?
Trastuzumab deruxtecan (T-DXd) versus physician’s choice of chemotherapy in HER2-low metastatic breast cancer.
How was HER2-low defined in DESTINY-Breast04?
IHC 1+ or IHC 2+ with negative ISH.
What were DESTINY-Breast04 median PFS values in the HR-positive cohort?
10.1 months with T-DXd versus 5.4 months with chemotherapy.
What was the DESTINY-Breast04 PFS hazard ratio?
HR 0.51; approximately 49% lower progression/death hazard in the compared groups.
What were DESTINY-Breast04 median OS values in the HR-positive cohort?
23.9 months with T-DXd versus 17.5 months with chemotherapy.
What was the DESTINY-Breast04 OS hazard ratio?
HR 0.64; approximately 36% lower death hazard.
What serious toxicity is associated with T-DXd?
Interstitial lung disease/pneumonitis, potentially fatal.
What ILD incidence and fatal incidence are quoted for DESTINY-Breast04?
12.1% ILD and 0.8% grade 5 fatal events in the trial report cited.
What did the phase III TOWER trial compare?
Blinatumomab versus salvage chemotherapy in adult relapsed/refractory B-cell ALL.
What were median OS results in TOWER?
7.7 months with blinatumomab versus 4.0 months with chemotherapy.
What was the TOWER overall survival HR and p-value?
HR 0.71 (95% CI 0.55–0.93), p = 0.01.
What CR rates with full haematologic recovery were reported in TOWER?
34% with blinatumomab versus 16% with chemotherapy within 12 weeks.
What did Kantarjian et al. (2017) publish?
The TOWER phase III blinatumomab versus chemotherapy results.
What did BLAST investigate?
Blinatumomab for B-ALL in morphological remission but with measurable residual disease.
What proportion became MRD-negative after one BLAST cycle?
78% of evaluable patients in the stated analysis.
What median overall survival is quoted for BLAST follow-up?
36.5 months; a follow-up estimate, not evidence of a randomized comparison.
What does MRD >10^-3 mean?
More than roughly 1 detectable malignant cell per 1,000 measured cells by the specified assay.
Why is blinatumomab step-dosed?
To reduce early cytokine release syndrome as CD3-engaged T cells activate.
What step-up blinatumomab doses are quoted?
9 μg/day in week 1, then 28 μg/day; schedule depends on indication and label.
What did HAVEN 1 test?
Emicizumab prophylaxis for haemophilia A with FVIII inhibitors.
What bleeding reduction is attributed to HAVEN 1?
87% lower treated bleeding rate with emicizumab prophylaxis versus no prophylaxis.
Who reported HAVEN 1 in 2017?
Oldenburg et al.
What did CHRYSALIS study?
Amivantamab in platinum-pretreated EGFR exon 20 insertion NSCLC.
What objective response rate was reported in CHRYSALIS?
40% in the specified EGFR exon 20 insertion cohort.
What median duration of response was reported in CHRYSALIS?
11.1 months.
What did phase III PAPILLON test?
First-line amivantamab plus chemotherapy versus chemotherapy in EGFR exon 20 insertion NSCLC.
What was PAPILLON’s key conclusion in the notes?
Amivantamab + chemotherapy significantly improved progression-free survival.
Who published PAPILLON according to the notes?
Zhou et al. (2023).
What did the EDITION 1 and 2 insulin trials compare?
Glargine U-300 versus glargine U-100.
What did EDITION 1/2 find for HbA1c lowering?
Similar HbA1c reduction with U-300 and U-100.
What safety advantage did glargine U-300 show in EDITION?
Less nocturnal hypoglycaemia in the cited comparisons.
What did SWITCH 1 and SWITCH 2 compare?
Insulin degludec versus glargine U-100.
What did SWITCH 1/2 show?
Less symptomatic, especially nocturnal, hypoglycaemia with degludec.
Which ultra-rapid lispro trials are cited?
PRONTO-T1D and PRONTO-T2D.
What outcome is emphasised in PRONTO trials?
Improved early post-meal glucose excursions versus conventional lispro in cited analyses.
What initial blood appearance times were quoted for Fiasp and standard aspart?
4 versus 9 minutes, respectively, in the lecture comparison.
What does the PIONEER clinical programme study?
Oral semaglutide in type 2 diabetes.
What did PIONEER 4 compare?
Oral semaglutide with liraglutide (and placebo in the study).
What weight-loss values are quoted for PIONEER 4?
4.4 kg with oral semaglutide versus 3.1 kg with liraglutide.
What was the primary cardiovascular design purpose of PIONEER 6?
A cardiovascular outcomes safety/noninferiority assessment of oral semaglutide.